Responsive Centered YouTube Video
Insights on treatment protocols and challenges in addressing reinfections in long Covid patients.
- Introduction to the challenges of treating long Covid patients with persistent symptoms. • 0:33
- Dr. Paul Merrick’s experience in developing early treatment protocols for Covid-19. • 1:02
- Discussion on the complexity of Covid-19 pathophysiology and the role of the spike protein. • 16:02
- Importance of addressing coagulation issues in acute, long Covid, and vaccine-injured patients. • 17:39
- Focus on the management of coagulation aspects in Covid-19 for effective treatment. • 18:09
- Exploration of treatment protocols by FLCCC and their role in early treatment strategies. • 19:05
- Addressing reinfections in long Covid patients and strategies to tackle brain infections. • 19:22
Exploration of physical properties of blood cells in relation to long-term consequences of COVID-19.
- Physical phenotyping involves probing the mechanical features of cells to extract internal information. • 33:03
- Application of mechanical probing on single blood cells to understand their development and differentiation. • 34:05
- Hematopoietic stem cells differentiate into various blood cell types with distinct internal structures. • 35:05
- Differences in microtubule organization between precursor cells and mature neutrophils can be measured through deformability. • 36:03
Investigation into altered blood cell properties in post-COVID patients reveals potential mechanisms for thrombosis.
- Physical properties of blood cells are altered in post-COVID patients, with red blood cells showing the most severe changes. • 36:31
- New nephritic techniques allow for high-speed measurement of cell deformability, enabling potential clinical applications. • 41:15
- Research indicates that recovered post-COVID patients still exhibit altered blood cell properties, possibly linked to long COVID symptoms. • 50:56
- Collaboration with ophthalmologists and researchers studying auto antibodies against receptors may provide insights into reduced blood flow in post-COVID patients. • 54:11
Discussion on thrombosis in COVID-19 patients, highlighting factors like endothelial injury, hypercoagulability, and turbulent blood flow.
- Endothelial injury, hypercoagulability, and turbulent blood flow are key factors in thrombosis. • 1:07:19
- Factors such as viremia of SARS-CoV-2, autoantibodies, and spike protein contribute to hypercoagulability. • 1:09:58
- Hypoxia can lead to vasoconstriction, hypertension, and subsequent endothelial injury. • 1:12:06
Insights on thrombosis development in long Covid patients and potential therapies.
- Endothelial damage activates contact pathway leading to thrombus formation. • 1:13:22
- Antibody interaction with SARS-CoV-2 spike protein can drive contact pathway activation. • 1:13:35
- Defective fibrinolysis contributes to thrombus persistence and tissue damage. • 1:14:14
- Reduced levels of protein C in patients with long Covid lead to enhanced clotting. • 1:15:56
- Neutrophil elastase can split spike protein into peptides that drive clotting. • 1:16:45
- Cytokines released by immune cells contribute to endothelial damage and thrombus formation. • 1:19:00
- Therapies include thrombopreventive drugs and thrombolytic agents to address clotting issues. • 1:23:05
- Clinical trials explore the use of activated protein C to manage thrombosis in long Covid patients. • 1:24:30
- Proposed concept involves adding additional constituents to heparin in apheresis for enhanced virus neutralization. • 1:25:07
- Natural products show promise in lysing clots with potential for low side effects. • 1:27:42
Overview of therapeutic apheresis in immune system disorders and its potential role in long COVID.
- Dr. Kiprov is the chief of the Division of Immunotherapy at California Pacific Medical Center. • 1:41:04
- Dr. Kiprov’s experience spans over a quarter of a century in therapeutic apheresis. • 1:41:27
- He has served on the American Society of Apheresis board of directors. • 1:41:33
- He has published extensively on therapeutic apheresis and immune system disorders. • 1:41:33
- He is involved in stem cell therapies and vaccine trials. • 1:41:55
- Dr. Kiprov is an expert in therapeutic apheresis for immune system disorders. • 1:42:03
- Dr. Kiprov’s work focuses on fostering immune system health and longevity. • 1:42:10
- He focuses on combining healthy eating habits and physical therapies for immune system health. • 1:42:10
- His unique approach includes a cookbook on boosting the immune system and preventing disease. • 1:42:18
- Therapeutic apheresis involves removing blood components like plasma for treatment. • 1:43:02
Overview of technologies and procedures used in treating various diseases like Long Covid.
- Historical background on bloodletting and the evolution of apheresis technology. • 1:43:10
- Introduction to therapeutic apheresis and its applications in removing specific blood components. • 1:47:03
- Explanation of double filtration technology for removing targeted components from plasma. • 1:51:22
- Discussion on the complex procedure of heparin-induced extracorporeal LDL precipitation. • 1:53:59
- Comparison of therapeutic plasma exchange using centrifugal devices as a safer and cost-effective option. • 1:56:04
- Impact of therapeutic apheresis on inflammatory factors and coagulation in diseases like Long Covid. • 1:57:06
- Evidence of phenotypic changes in T cells and proteomic effects through therapeutic plasma exchange. • 1:58:07
- Observations on cell subset alterations and improvements in patients with Long Covid post-treatment. • 1:59:04
- Case study demonstrating rapid improvement in lung function and overall health post-apheresis treatment. • 2:01:15
- Discussion on post-infection immune dysregulation leading to various chronic conditions and similarities in pathogenesis. • 2:03:06
- Insights on personalized treatment for Long Covid patients using plasma exchange and immunomodulatory therapy. • 2:03:40
- Patients with Long Covid exhibit autoantibodies, high inflammatory markers, and coagulation abnormalities. • 2:03:40
- Post-infection and post-vaccination autoimmune syndromes, including antiphospholipid syndrome, are observed. • 2:04:10
- Plasma exchange is used to remove cytokines, autoantibodies, immune complexes, and amyloid in Long Covid patients. • 2:06:25
- Stratification of patients based on cytokines, inflammation, autoantibodies, and coagulation status is crucial for treatment success. • 2:15:01
- Patients find clinics through publications and internet, seeking personalized treatment for Long Covid. • 2:17:04
- Predictors for successful treatment outcomes in plasma exchange or help apheresis are still under investigation. • 2:20:07
Insights on diverse mechanisms and individualized treatments for long COVID patients.
- Patients with long COVID exhibit individual responses to therapies, requiring personalized treatment. • 2:20:55
- Challenges in understanding why some patients respond dramatically to a therapy while others do not. • 2:21:14
- Long COVID and post-vaccine injuries show significant individual variation in treatment responses. • 2:21:58
- Plasma exchange may provide temporary relief but sustained cure for long COVID remains elusive. • 2:23:27
- Autoantibodies in vaccinated patients may lead to unexpected severe outcomes, such as sudden cardiac arrest. • 2:27:30
- Raised IgE levels and diverse mechanisms like bacteriophage activity and gut toxins play a role in long COVID. • 2:31:05
- Immune complexes, complement cascade, and endothelial damage are potential pathways for severe outcomes in long COVID patients. • 2:34:01
- Direct viral effects on pacemaker cells and thrombus formation in coronary arteries may contribute to sudden cardiac events in long COVID. • 2:35:02
- Autopsy and further research are crucial to understand the underlying pathology of severe outcomes in long COVID patients. • 2:35:39
Insights on autoimmune response, spike protein, and diverse antibodies in Long Covid patients.
- Long Covid linked to autoimmune response triggered by spike protein. • 2:36:20
- Presence of diverse antibodies in Long Covid and post-vaccine injury cases. • 2:47:02
- Concerns raised about the quality control and diversity of mRNA in vaccines. • 2:47:52
- Proposed layered approach for interventions in managing Long Covid. • 2:50:06
Discussion on the importance of addressing diet, viral reservoirs, and long-term solutions for long Covid.
- Patients often overlook the impact of diet on their health, which can exacerbate symptoms. • 2:52:08
- Nutraceuticals like curcumin and black seed oil show promise in improving outcomes for long Covid. • 2:52:31
- Long Covid may involve viral reservoirs in the body, such as gut crypts and sinuses, contributing to persistent symptoms. • 3:04:00
- Addressing viral hideouts and viral sources is crucial for eradicating the virus and reducing symptom recurrence. • 3:05:31
Insights and recommendations from experts on addressing long Covid and thrombosis
- Individualized approach crucial for long Covid treatment based on patient presentation. • 3:07:29
- Importance of identifying primary immune triggers in long Covid symptoms. • 3:07:57
- Focus on restoring tight junction integrity in the gut to address autoimmune diseases. • 3:09:00
- Need for personalized treatment plans for long Covid patients due to varied presentations. • 3:11:20
- Emphasis on finding the underlying cause (‘fire’) of symptoms in long Covid for effective treatment. • 3:14:04
- Call for collaboration, research, and treatment development for long Covid patients. • 3:18:33
- Urgent need to shift focus towards treatment rather than observation in long Covid research. • 3:22:07
Cutting-edge breakthrough thinking on Long Covid Coalition Congress findings.
- Importance of combining knowledge for patient care. • 3:23:10
- Acknowledgment of organizers’ efforts in bringing experts together. • 3:23:24
- Recognition of experts’ global expertise. • 3:23:52
- Appreciation for coalition’s efforts in organizing the event. • 3:23:58
- Wishes for a good evening to all participants. • 3:24:04
